Clinical endocannabinoid deficiency (CECD) revisited: Can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
Smith S.C.,C3 International |
Wagner M.S.,C3 International
Neuroendocrinology Letters | Year: 2014
OBJECTIVES: Ethan B. Russo's paper of December 1, 2003 explored the concept of a clinical endocannabinoid deficiency (CECD) underlying the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome and other functional conditions alleviated by clinical cannabis. METHODS: Available literature was reviewed, including searches via the National Library of medicine database and other sources. RESULTS: A review of the literature indicates that significant progress has been made since Dr. Ethan B. Russos landmark paper, just ten years ago (February 2, 2004). Investigation at that time suggested that cannabinoids can block spinal, peripheral and gastrointestional mechanisms that promote pain in headache, fibromyalgia, irritable bowel syndrome and muscle spasm. CONCLUSION: Subsequent research has confirmed that underlying endocannabinoid deficiencies indeed play a role in migraine, fibromyalgia, irritable bowel syndrome and a growing list of other medical conditions. Clinical experience is bearing this out. Further research and especially, clinical trials will further demonstrate the usefulness of medical cannabis. As legal barriers fall and scientific bias fades this will become more apparent. © 2014 Neuroendocrinology Letters.
Pelham R.,C3 International |
Spears M.,C3 International |
Pozvonkov M.,C3 International
NPRA Annual Meeting Technical Papers | Year: 2010
A discussion on the mechanisms causing coke deposition on delayed coker furnace tubes and C3 International's MIST mitigation of this problem covers an overview of the process, including chemical reactions, metal catalyzed coking, and chemical reaction summary; fouling mitigation using C3's MIST Technology; less adherent coke due to C3's MIST technology; and benefits of C3's MIST technology. This is an abstract of a paper presented at the NPRA Annual Meeting (Phoenix, AZ 3/21-23/2010).